#United States #Atlanta #Biocodex #Stiripentol #Dravet Syndrome

Biocodex Unveils Promising Research at AES 2025 Annual Meeting in Atlanta

Biocodex, a global leader in pharmaceuticals and a pioneer in addressing rare pediatric conditions, is set to showcase its latest findings at the American Epilepsy Society (AES) Annual Meeting 2025, scheduled from December 5 to 9 in Atlanta, Georgia. The company will present a total of 12 enlightening studies, focusing primarily on the use of stiripentol as a therapeutic option for patients suffering from Dravet syndrome, a severe form of epilepsy that typically manifests in infancy.

Dravet syndrome is characterized by prolonged seizures that can lead to significant developmental delays. As awareness of this condition grows, so does the need for effective treatment options. Stiripentol has emerged as an essential part of a multi-drug regimen for managing this challenging condition, particularly when combined with clobazam. The upcoming meeting serves as a platform for Biocodex to disseminate valuable insights and research findings that could potentially enhance clinical practices.

Dr. Carla Schad, the North American Medical Officer at Biocodex, expressed enthusiasm about participating in this year's AES conference. She emphasized, “Our attendance at AES this year reflects our unwavering commitment to providing healthcare professionals and researchers with updated data, while fostering meaningful connections with thought leaders and advocates. At Biocodex, our priority remains the well-being of patients.”

Key Findings and Posters

Among the noteworthy presentations will be the following critical studies:

• - Real-World Use and Effectiveness of Stiripentol: Results from the STIRUS Study will be showcased, highlighting the real-life application of stiripentol in American patients diagnosed with Dravet syndrome. This study aims to provide evidence supporting stiripentol’s effectiveness and safety.

• - Long-Term Effectiveness of Stiripentol: This retrospective analysis reviews data from a three-year Japanese post-marketing surveillance study, investigating how consistently stiripentol can reduce seizure occurrences in patients.

• - Evaluating Practices Surrounding SUDEP: Addressing the crucial topic of sudden unexpected death in epilepsy (SUDEP), this study will investigate current healthcare practices and communication strategies surrounding this phenomenon.

Conference attendees can also expect to explore a range of additional studies, including:

• - The necessity of reintroducing stiripentol after weaning in certain patients.
• - How stiripentol's use correlates with lower mortality rates in real-world cohorts.
• - Consensus recommendations for rational polytherapy in Dravet syndrome management.

Educational Symposia

In addition to its research presentations, Biocodex will host two informative symposia designed to enhance understanding of Dravet syndrome and its treatment. These sessions aim to promote collaborative learning and provide up-to-date recommendations for diagnosing and managing Dravet syndrome:

1. Diagnostic and Treatment Disparities in Dravet Syndrome: This symposium will discuss the latest data on disparities in the diagnosis and treatment of Dravet syndrome, alongside recommended guidelines established by leading pediatric neurologists.
- Speaker: Dr. Julie Ziobro, Assistant Professor of Pediatrics at the University of Michigan, along with representatives from the Dravet Syndrome Foundation and Biocodex.
- Date & Time: Saturday, December 6, from 1:30 PM to 2:30 PM.

2. Optimizing Treatment Options for Dravet Syndrome Patients: Focusing on Dravet syndrome signs and symptoms, this session will cover the importance of early intervention and available treatment options.
- Speaker: Dr. James W. Wheless, a renowned expert in epilepsy management.
- Date & Time: Saturday, December 6, from 3:30 PM to 4:30 PM.

The AES 2025 Annual Meeting is poised to be a significant opportunity for Biocodex to share invaluable research with the medical community and connect with fellow advocates in the epilepsy field. As efforts continue to enhance treatments for Dravet syndrome, it is clear that the commitment to patient welfare remains at the forefront of Biocodex's endeavors.

About Biocodex

Founded in 1953, Biocodex is a family-owned company based in France, devoted to advancing health through innovative pharmaceutical solutions. Operating in 115 countries, Biocodex is recognized for its deep commitment to microbiota health and has developed expertise in various sectors, including orphan diseases, women’s health, and neurology. For further information about Biocodex and its initiatives, visit www.biocodex.us. Additionally, for information on DIACOMIT® (stiripentol), visit www.diacomit.com.